title: Therapy of relapsed or refractory low-grade follicular lymphomas: factors associated with complete remission, survival and time to treatment failure.
abstract: Patients with relapsed low-grade follicular lymphomas (LGFL) frequently respond to subsequent therapy and can have long survival, but are rarely cured. Factors associated with complete remission (CR) rate, length of survival, and time to treatment failure (TTF) after relapse are not well known. We assessed such factors by multivariate analysis in a retrospective review of 95 patients with relapsed LGFL treated with investigational chemotherapy regimens at our institution. The CR rate after therapy was 22%; the likelihood of achieving CR was inversely associated with the number of previous treatment failures (P less than 0.001) and serum LDH level (P less than 0.05). Both the presence of constitutional symptoms and a history of more than two previous treatment failures were associated with shortened survival and TTF. Hemoglobin level was also significantly associated with survival. Prognostic models for survival and TTF were derived to define patient groups with different projected outcomes after therapy for relapsed disease. The results of this study can be used to select patients for new investigational treatments and to evaluate the outcome of such therapies.
authors.affiliation: Department of Hematology, University of Texas, M.D. Anderson Cancer Center, Houston.
authors.forename: J A
authors.initials: JA
authors.lastname: Spinolo
authors.forename: F
authors.initials: F
authors.lastname: Cabanillas
authors.forename: D O
authors.initials: DO
authors.lastname: Dixon
authors.forename: S M
authors.initials: SM
authors.lastname: Khorana
authors.forename: P
authors.initials: P
authors.lastname: McLaughlin
authors.forename: W S
authors.initials: WS
authors.lastname: Velasquez
authors.forename: F B
authors.initials: FB
authors.lastname: Hagemeister
authors.forename: J R
authors.initials: JR
authors.lastname: Redman
authors.forename: F
authors.initials: F
authors.lastname: Swan
mesh_terms: D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001706:Biopsy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008224:Lymphoma, Follicular / Q000188:drug therapy / Q000401:mortality* / Q000473:pathology; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000401:mortality* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D008954:Models, Biological; D011379:Prognosis; D012189:Retrospective Studies; D012307:Risk Factors; D013997:Time Factors